| Sep 12 |
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
|
| Sep 5 |
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 26 |
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
|
| Aug 15 |
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
|
| Aug 14 |
Armata Pharmaceuticals GAAP EPS of -$0.25
|
| Aug 13 |
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
|
| Jul 30 |
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
|
| Jul 11 |
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
|
| Jul 10 |
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
|
